Streetbeat News

Products Services

HMC

KD

Honda Motor Europe has renewed and expanded its IT partnership with Kyndryl to enhance its IT infrastructure. This collaboration aims to improve Honda's operational efficiency and innovation capabilities.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:09 pm

NTRA

Natera, Inc. (NASDAQ:NTRA), a leader in cell-free DNA and genetic testing, announced surpassing 200 peer-reviewed publications featuring its technology. These publications, in top journals like Science and NEJM, cover Natera's advancements in women's health, oncology, and organ health, demonstrating its commitment to evidence-based innovations that improve patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:08 pm

BRAG

Bragg Gaming Group Inc. (BRAG) has entered into an international distribution agreement with Light & Wonder to feature Bragg's online casino content on Light & Wonder's ecosystem. This deal includes games from Bragg's proprietary studios and exclusive content from its Powered by Bragg partners, expanding Bragg's reach in European, USA, and Canadian markets. The collaboration aims to enhance Bragg's game exposure and strengthen its casino offering with new titles.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:07 pm

ORCL

Oracle has received accreditation for three cloud regions to host U.S. Department of Defense (DoD) secret classified workloads, achieving Defense Information Systems Agency Impact Level 6 Authorization. This positions Oracle's cloud as a high-performance, cost-effective solution for classified defense workloads.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:04 pm

AILE

ANL

CDE

IAUX

INFA

LI

MNDR

TSLA

Tesla, Inc. (TSLA) shares fell 3.6% in pre-market trading after announcing a $2,000 price cut for its U.S. electric-vehicle lineups, affecting its shares and those of other companies. iLearningEngines, Inc. (AILE), Adlai Nortye Ltd. (ANL), Li Auto Inc. (LI), Mobile-health Network Solutions (MNDR), Coeur Mining, Inc. (CDE), i-80 Gold Corp. (IAUX), and Informatica Inc. (INFA) also saw declines in pre-market trading due to various factors including market reactions to Tesla's price cut, pullbacks in precious metals prices, and acquisition talks.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 12:04 pm

CPNG

TAST

Two consumer discretionary stocks, Carrols Restaurant Group, Inc (TAST) and Coupang, Inc. (CPNG), are highlighted as overbought with RSI values above 70, signaling potential short-term performance concerns. TAST's stock rose after a 13D filing showed a 3.27% stake by Gabelli Funds, while CPNG plans to raise its membership fees by 58%, affecting its stock negatively.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 12:03 pm

ELAB

Elevai Labs, Inc. (ELAB) has entered into a distribution agreement with ILIA International Ltd. for the distribution of its products in Taiwan. This strategic move aims to expand ELAB's market presence in Asia.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:03 pm

ADIL

Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been granted a US patent (number 11957664) for a combination of its proprietary genetic diagnostic and its lead investigational drug, AD04, for treating alcohol use disorder (AUD) and other drug dependencies such as opioid use disorder (OUD). This patent strengthens Adial's intellectual property portfolio, covering specific genotypes for targeted treatment. The addressable market for these treatments in the U.S. is estimated at $40 billion. Additionally, Adial has previously received a patent for AD04 targeting the serotonin transporter gene for potential OUD treatment and published positive clinical results and safety profiles for AD04.

Portfolio Pulse from Vandana Singh

April 22, 2024 | 12:00 pm

ADIL

Adial Therapeutics has expanded its intellectual property protection with a new patent covering the combination of its proprietary genetic diagnostic to identify patients with specific genotypes.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:00 pm

JNJ

The European Commission (EC) has approved Carvykti for the treatment of relapsed or refractory multiple myeloma, according to Bloomberg. This approval marks a significant milestone for patients with this condition, offering a new therapeutic option. Johnson & Johnson (JNJ), likely involved in the development or distribution of Carvykti, may see a positive impact from this news.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:57 am